论文部分内容阅读
目的分析研究小剂量辛伐他丁治疗高脂血症的治疗效果及安全性。方法回顾性分析2012年3月～2012年9月期间在我院治疗的72例原发性高脂血症患者的临床资料。将72例患者随机分为观察组和对照组各36例,观察组给予辛伐他丁片口服治疗,对照组给予洛伐他汀口服治疗,疗程12周,观察两组临床疗效及不良反应。结果对照组显效21例,有效9例,无效6例,有效率为83.33%;观察组显效25例,有效7例,无效4例,有效率为88.89%,两组疗效比较差异无统计学意义(P>0.05)。两组间低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、总胆固醇(TC)和甘油三酯(TG)比较差异有统计学意义(P<0.05)。结论小剂量辛伐他丁治疗原发性高脂血症,降脂效果显著,且不良反应少,是值得广泛推广的一种安全有效的冠心病一、二级预防药物。
Objective To analyze the therapeutic effect and safety of low dose simvastatin in the treatment of hyperlipidemia. Methods The clinical data of 72 patients with primary hyperlipidemia treated in our hospital from March 2012 to September 2012 were analyzed retrospectively. Seventy-two patients were randomly divided into observation group and control group, with 36 cases in each group. The observation group was treated with simvastatin tablets orally. The control group was treated with lovastatin orally for 12 weeks. The clinical efficacy and side effects were observed. Results In the control group, 21 cases were markedly effective, 9 cases were effective and 6 cases were ineffective. The effective rate was 83.33%. In the observation group, 25 cases were markedly effective, 7 effective and 4 ineffective, with an effective rate of 88.89%. There was no significant difference between the two groups (P> 0.05). The differences of LDL-C, HDL-C, TC and triglyceride between the two groups were statistically significant (P <0.05). Conclusion Low-dose simvastatin treatment of primary hyperlipidemia, lipid-lowering effect is significant, and less adverse reactions, is worthy of widespread promotion of a safe and effective primary and secondary prevention of coronary heart disease.